Monday, October 18, 2010

Biosphosphonates get an FDA Warning (Fosamax, Actonel, Boniva)

FOSAMAXImage by flap via FlickrThe FDA last week asked that certain drug makers add a  warning to the label of all bisphosphonates, which include Boniva, Actonel, and FosamaxHealth Canada also announced last week that there is evidence that women taking bisphosphonates could have increased risk of thigh bone fractures. The drugs are currently under “safety review” in Canada.
FDA reps said the risk of  certain fractures were highest in those who took the drugs for five years or more, according to data provided by the American Society for Bone Mineral Research Task Force.
A deterioration of the jaw bone has also been associated with bisphosphonates, though osteoporosis experts emphasize that, for those with the disease, the drugs' benefits still far outweigh the risks. Experts don't know for certain if bones continue to benefit from the medications beyond the five or 10 year mark.
Enhanced by Zemanta